Reclast is marketed by Novartis, was was approved by the FDA for treatment of Paget's Disease in 2007. Administered by infusion, the main ingredient, zoledronioc acid, is also marketed by Novartis as Zometa for use in the treatment of skeletal fractures in patients with cancers such as multiple myeloma and prostate. It has also been used to treat osteoporosis. For the treatment of Paget's patients recieve a single dose, annually. Results of studies for Reclast were published in the Sep 1, 2005 issue of the New England Journal of Medicine.
The cause of Paget's Disease is unknown. The disease causes an abnormal breakdown of bone tissue, followed by abnormal bone formation. The new bone is enlarged but weaker. The disease often effects the bones of the arms, collarbones, legs, pelvis, spine and skull.
2011
2013
The above patient studies were obtained at 3 hours following the injection of 25 mCi Tc MDP. Whole body bone scans with post void images of the pelvis were obtained. The study from 2013 demonstrates marked decreased activity in the right hemipelvis, following Reclast therapy, as compared to the study from 2011.
